Carisma Therapeutics Inc.
We are a biotechnology company focused on applying our industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. We have created a comprehensive set of platform technologies to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called mye…
$0.00
+$0.00 (+0.00%)
Price from 4 days ago
The business is unprofitable at the operating level (-317.24% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 31.5% YoY with margins expanding 278.3pp.
ROIC dropped from -62.43% to -305.71%, capital efficiency is deteriorating. Negative free cash flow of -$60M. The business is consuming cash, not generating it.
0.0x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$53M
▲ +31.5% YoY
Net Income (TTM)
$8M
▲ +30.4% YoY
Op. Margin
20.62%
▲ +278.3pp YoY
ROIC
471.61%
▼ -243.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$22M
▲ +27.1% YoY
Op. Cash Flow (TTM)
-$22M
▲ +26.2% YoY
Net Debt
-$2M
Net Cash Position
Cash & Equiv.
$3M
Continue Research
SourceComputed from the 10-Q filed 5 Nov 2025, covering the period ending 30 Sept 2025, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.
Price from market data, last close as of 14 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Carisma Therapeutics (CARM) overvalued?
At a P/E of 0.0, Carisma Therapeutics (CARM)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Carisma Therapeutics scores 60/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Carisma Therapeutics a high-quality business?+
Carisma Therapeutics scores 60 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 20.6% operating margin and a 471.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Carisma Therapeutics a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh CARM's valuation and scores 60/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.